Prostate Cancer Trial, Recruiting NCT04612907 Sponsor: Umeå University Condition: Prostate Cancer
Back to Prostate Cancer

Prostate Cancer Trial, Recruiting

NCT04612907
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have signed a consent form agreeing to take part in the study
  • People whose prostate cancer has been confirmed through a tissue sample (biopsy or similar test)
  • People with prostate cancer that has spread to a limited number of sites in the body — specifically, no more than 4 areas in the bones (at any location) and/or any number of lymph nodes, with no spread to internal organs such as the liver or lungs
  • People who have completed a baseline quality-of-life questionnaire called the E-PROM at the start of the study

Who may not be able to join:

  • People whose prostate cancer has spread widely, including any spread to internal organs (such as the liver, lungs, or other visceral sites)
  • People who are not able to follow the study procedures and requirements
  • People who have other health conditions or are taking medications that may increase the risk of harmful side effects from radiation treatment (confirm with trial site)
  • People whose radiation treatment would begin more than nine months after their prostate cancer was first diagnosed
  • People who have severe urinary (bladder/urination) problems, as measured by a standard symptom score above 20 on the International Prostate Symptom Score (IPSS)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Camilla of T Karlsson, Cancercentrum Umeå University

Phone: +46 90 785 3296

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Umeå University
Registry
ClinicalTrials.gov
Start date
31 October 2022
Est. completion
30 June 2026

Where this trial is recruiting

🇸🇪 Sweden

Primary endpoints

Toxicity as scored by PROM (Patient Reported Outcome Measures) at 8 weeks; Toxicity as scored by PROM at 8 weeks

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov